A number of global pharma firms have pulled or paused U.K. investment plans amid waning government support and drug pricing talks.
Get this delivered to your inbox, and more info about our products and services.
Big pharma firms have paused nearly £2bn in UK investments this year
Swiss drug giant looks for ways to lower U.S. prices amid tariff threat and admits Americans 'pay for a large part of the innovations' | Fortune
AstraZeneca pauses £200m Cambridge expansion amid NHS pricing row
Who benefits if NHS drug prices soar? Donald Trump and big pharma. Just one more way he’s menacing Britain | Polly Toynbee
A fresh ultimatum demanding "binding commitments" to lower U.S. drug prices sent pharma firms scrambling Friday.
Pharma giants are navigating President Trump's demands to bring U.S. drug prices in line with other developed nations.
The U.K. is in the midst of a falling out with big pharma over drug pricing. Merck has walked away from a £1 billion facility in…
Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears
Markets failed to rally despite what analysts said was a clear win for the European pharmaceutical sector in a trade update…
Drugmakers rally after Pfizer agreement as Most Favored Nation plans still loom over sector.
